NLRP3 and coronary artery disorder: CANTOS and several colchicine studies (COLCOT, LoDoCo, LoDoCo2) have confirmed the inflammatory hypothesis of coronary disease and demonstrated that targeting residual inflammatory risk and possibly the NLRP3 pathway may serve as an important strategy in reducing major adverse cardiovascular events.